PharmaFocus Today – Page 159 – media

Switching to the Beijing Stock Exchange! The leading fungus detection company plans to go public again

Recently, according to the official website of the Beijing Stock Exchange, the Beijing Stock Exchange Listing Committee is scheduled to hold the 26th review meeting of 2024 at 9:00 am on December 27, 2024. The issuer under review is Dana (Tianjin) Biotech Co., Ltd. (hereinafter referred to as Dana Biotech). It is worth mentioning that at present, the exchanges have not announced the convening of IPO review meetings, and Dana Biotech’s meeting may become the last IPO meeting in 2024. Dana Biotech was founded in 2014 and is mainly committed to the research and development, production and clinical application of early rapid in vitro diagnostic products for invasive fungal diseases (IFD). It is a company that independently provides combined detection solutions and all products for invasive fungal infections. Its R&D team is also very strong. The leader and chief scientist of the R&D team, Zhou Zeqi, is a Ph.D. from ...
- Source: drugdu
- 354
- January 3, 2025
Tirzepatide enters another 10 billion market

Recently, Eli Lilly announced that the FDA has approved Zepbound (tirzepatide) for the new indication of treating moderate to severe obstructive sleep apnea (OSA) in obese people. While using Zepbound, you should reduce your calorie diet and increase physical exercise. The approval of the OSA indication has given Eli Lilly another heavyweight bargaining chip in its competition with its strongest rival Novo Nordisk. Obstructive sleep apnea (OSA) is a respiratory disease in which apnea and/or hypopnea occur repeatedly during sleep. During sleep, the throat and tongue muscles relax, leading to airway obstruction, and air circulation is blocked, causing apnea or weakening of breathing. OSA is common in obese and middle-aged and elderly people, and can cause complications such as coronary atherosclerotic heart disease, heart failure, arrhythmia, and diabetes. Clinical manifestations include snoring, loud snoring, feeling suffocated or waking up at night, and severe cases of cognitive decline and abnormal behavior. ...
- Source: drugdu
- 858
- January 2, 2025
Big news! The first cell-impermeable stent is approved by the FDA for marketing

Recently, Meritone announced that its cell-impermeable stent—Wrapsody was approved by the FDA for marketing. This is the first product approved by the FDA for the treatment of vascular access stenosis or thrombosis in hemodialysis patients. It is reported that Meritone will start commercialization in the United States next year. Founded in 1987, Meritone is a leading medical device manufacturer that produces devices used in cardiac and radiological interventional surgery. Meritone’s product line includes interventional filling devices and accessories, diagnostic and therapeutic catheters and guidewires, disposable pressure monitoring equipment, contrast agent management systems, non-vascular stents, thrombolytic catheters and syringes and needles. The company is committed to meeting the needs of global cardiology and radiology experts through product research and development and high-quality production. Hemodialysis is currently the most widely used blood purification treatment method, suitable for most patients with acute and chronic renal failure. According to statistics and forecasts from Global ...
- Source: drugdu
- 454
- January 2, 2025
Subsidiary’s Drug Clinical Trial Terminated, R&D Investment of 121 Million Yuan

Recently, Tian Tan Bio announced that its subsidiary, China National Pharmaceutical Group Wuhan Biological Products Co., Ltd., has developed “Intravenous COVID-19 Human Immunoglobulin (pH4)” which is currently in the Phase II clinical trial stage. After a comprehensive evaluation, the company has decided to terminate the Phase II clinical trial and subsequent research and development of the drug. According to the announcement, the total R&D investment for the intravenous COVID-19 human immunoglobulin (pH4) amounts to 121 million yuan, which includes research and development expenses and equipment purchase costs. Among these, the cumulative R&D expenses totaled 117 million yuan, already accounted for in previous fiscal periods, while -0.04 thousand yuan will be accounted for in the 2024 fiscal year. Data shows that Tian Tan Bio’s main business is the research and production of blood products using healthy human plasma or plasma from specifically immunized healthy individuals as raw materials, employing genetic recombination ...
- Source: drugdu
- 240
- January 2, 2025
Lukang Pharmaceutical raises 1.2 billion yuan through private placement to build a high-end intelligent manufacturing workshop for formulations and a biopesticide base

On December 20th, Lu Kang Pharmaceutical announced that the company plans to issue stocks to no more than 35 eligible investors, including the controlling shareholder Hualu Group, with a total fundraising amount of no more than 1.2 billion yuan. After deducting the issuance expenses, the funds will be used for the construction of high-end intelligent manufacturing workshops (total investment 442 million yuan), biopesticide base construction (total investment 432 million yuan), new drug research and development projects (total investment 210 million yuan), and supplementary working capital (200 million yuan). According to the official website, Lu Kang Pharmaceutical is a state-owned comprehensive pharmaceutical enterprise established in 1966. It was listed on the main board of the Shanghai Stock Exchange in 1997 and became a subsidiary of Hualu Holdings Group Co., Ltd. (hereinafter referred to as “Hualu Group”) in 2006. For the 1.2 billion yuan private placement fundraising, Lu Kang Pharmaceutical stated that ...
- Source: drugdu
- 562
- January 1, 2025
Yiming Biotech Completes RMB 200 Million Pre-D Round of Financing

Recently, Jiangsu Yiming Biotechnology Co., Ltd. (hereinafter referred to as “Yiming Biotech”) announced the successful completion of a new round of strategic financing of nearly RMB 200 million. This Pre-D round of financing was jointly invested by Beijing Changping Industrial Development Investment Fund and Beijing Pharmaceutical and Health Industry Investment Fund. It is another round of financing obtained by Yiming Biotech after the C+ round of financing in April 2023. Yiming Biotech said that as a bridge for ATMPs to go global and commercialize, it has been recognized and strongly supported by multiple investors in the current complex market environment. This round of financing will be used to further support the construction of Yiming Biotech’s ATMPs CDMO commercial production base, promote technology iteration, enhance the service capabilities of the CDMO global service network, consolidate the company’s core competitiveness in the ATMPs drug technology track, and create a large CDMO service ...
- Source: drugdu
- 363
- January 1, 2025
744 million! Medical Device Dark Horse completes C round of financing again

Recently, Precision Neuroscience (hereinafter referred to as Precision) announced that it has completed a new round of C round of financing of US$102 million (approximately RMB 744 million), bringing its total funds to US$155 million. Investors participating in this round of financing include General Equity Holdings, B Capital, Stanley F. Druckenmiller’s Duquesne Family Office and Steadview Capital. This round of financing will be used to expand Precision’s team, advance clinical research, and improve future versions of its artificial intelligence-driven brain implants. These implants are designed to enable severely paralyzed users to operate digital devices such as computers and smartphones simply by thinking. On November 6 this year, Precision also completed a C round of financing, with a financing scale of US$93 million (approximately RMB 679 million). Founded in 2021, Precision is a company focused on developing brain-computer interface (BCI) technology. Its goal is to bring advanced brain-computer interface technology to ...
- Source: drugdu
- 381
- January 1, 2025
The Rise of Domestic Production

Proton therapy is known as the “crown jewel” of tumor radiotherapy for its excellent performance, representing the highest level of radiotherapy technology. This technology utilizes the high-energy properties of proton beams to accurately strike tumor tissues while minimizing damage to surrounding normal tissues, bringing unprecedented treatment hope to cancer patients. According to the latest statistics, the number of proton heavy ion therapy centers worldwide has exceeded one hundred, which fully demonstrates the widespread recognition and application of proton therapy technology worldwide. According to market predictions, the global proton therapy market is expected to reach nearly 1.6 billion US dollars by 2031, which fully reflects the enormous potential and broad prospects of proton therapy technology. As 2024 is coming to an end, Instrumental Home has conducted a statistical analysis of the progress of proton therapy system projects in mainland China (based on public reports), and found that there are already 7 ...
- Source: drugdu
- 872
- January 1, 2025
Huiminbao’s “prisoner’s dilemma”

“Two people in my family were hospitalized, and both had Huiminbao, but not a penny was reimbursed.” When asked whether he would renew Huiminbao, netizen A answered like this. The subtext is: not renewing. It seems to be a very common thing to buy Huiminbao but not get protection. Behind this, it may also be Huiminbao’s helpless move. The nature of universal benefits has led to its extremely wide audience, but in order to avoid losses, Huiminbao has to set a relatively high deductible. In the past, the deductible of some products exceeded 20,000 yuan. However, most of the 20,000 yuan paid out of pocket in addition to medical insurance reimbursement is for major diseases. This also makes Huiminbao look more like major disease insurance, which has little to do with the market’s perception of “benefiting the people”. Of course, there are also Huiminbao with higher compensation rates, but they ...
- Source: drugdu
- 512
- January 1, 2025
Pioneer in going global, Sinopharm brings good news again. Inflixi, a newly introduced product, has been approved in Indonesia

Recently, Sinopharm (stock code: 688136) introduced its product – Infliximab for Injection (class stop) ®） Successfully approved for listing in Indonesia. The Southeast Asian pharmaceutical market has always been one of Sinopharm’s important advantage markets overseas. The approval of Inflixi in Indonesia further expands the sales area of the drug and provides new treatment options for local patients. Quickly approved for listing, Inflixi’s overseas progress refreshes Infliximab for injection (class stop) ®）， Approved for marketing by the National Medical Products Administration in July 2021, it is the first domestically approved biosimilar drug of Infliximab, mainly used for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, adult ulcerative colitis, adult and children over 6 years old with Crohn’s disease and fistula Crohn’s disease. In 2021 and 2022, Sinovac Pharmaceutical and Taizhou Mabotaike Pharmaceutical Co., Ltd. signed agreements to obtain biosimilars of Infliximab (class stop) ®） Commercial rights in over 30 countries ...
- Source: drugdu
- 471
- December 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.